Zoetis, Inc. (ZTS)
77.10
-0.63
(-0.81%)
USD |
NYSE |
Aug 24, 16:00
77.45
+0.35
(+0.45%)
After-Hours: 20:00
Zoetis Enterprise Value : 39.75B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 39.75B |
| August 20, 2026 | 38.63B |
| August 19, 2026 | 39.32B |
| August 18, 2026 | 38.19B |
| August 17, 2026 | 37.78B |
| August 14, 2026 | 38.12B |
| August 13, 2026 | 38.97B |
| August 12, 2026 | 38.02B |
| August 11, 2026 | 38.77B |
| August 10, 2026 | 38.55B |
| August 07, 2026 | 37.65B |
| August 06, 2026 | 39.56B |
| August 05, 2026 | 38.37B |
| August 04, 2026 | 39.05B |
| August 03, 2026 | 39.49B |
| July 31, 2026 | 39.57B |
| July 30, 2026 | 39.05B |
| July 29, 2026 | 39.84B |
| July 28, 2026 | 39.66B |
| July 27, 2026 | 39.42B |
| July 24, 2026 | 38.77B |
| July 23, 2026 | 38.45B |
| July 22, 2026 | 38.29B |
| July 21, 2026 | 38.77B |
| July 20, 2026 | 39.12B |
| Date | Value |
|---|---|
| July 17, 2026 | 39.27B |
| July 16, 2026 | 39.41B |
| July 15, 2026 | 38.43B |
| July 14, 2026 | 38.24B |
| July 13, 2026 | 38.79B |
| July 10, 2026 | 38.86B |
| July 09, 2026 | 38.66B |
| July 08, 2026 | 38.66B |
| July 07, 2026 | 39.16B |
| July 06, 2026 | 38.80B |
| July 02, 2026 | 38.54B |
| July 01, 2026 | 37.57B |
| June 30, 2026 | 37.32B |
| June 29, 2026 | 38.09B |
| June 26, 2026 | 39.28B |
| June 25, 2026 | 40.01B |
| June 24, 2026 | 40.16B |
| June 23, 2026 | 39.60B |
| June 22, 2026 | 39.20B |
| June 18, 2026 | 40.38B |
| June 17, 2026 | 39.77B |
| June 16, 2026 | 40.64B |
| June 15, 2026 | 40.90B |
| June 12, 2026 | 40.74B |
| June 11, 2026 | 41.51B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 423.37B |
| Elanco Animal Health, Inc. | 15.36B |
| Boston Scientific Corp. | 85.09B |
| Pfizer Inc. | 211.77B |
| Phibro Animal Health Corp. | 2.183B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 691.00M |
| Revenue (Quarterly) | 2.468B |
| Total Expenses (Quarterly) | 1.777B |
| EPS Diluted (Quarterly) | 1.654 |
| Gross Profit Margin (Quarterly) | 71.47% |
| Profit Margin (Quarterly) | 28.00% |
| Earnings Yield | 7.88% |
| Operating Earnings Yield | 10.80% |
| Normalized Earnings Yield | 8.149 |